Protalix Biotherapeutics Inc (NYSEMKT:PLX) To Provide Corporate Update And Financials For 1Q2017

0
3479

Protalix Biotherapeutics Inc (NYSEMKT:PLX) has announced that it would be releasing its financial results for the 1Q2017, as well as a corporate update, on May 10, 2017. The company has also stated that it would hold a conference call, on the same day. A replay of the call would be made available on Protalix’s website, for a period of 2-weeks, following the release.

The announcement comes shortly after the released its pre-clinical results from the PRX-102, in Fabry mice. The study is being led by Prof. Raphael Schiffmann, the director of the Institute of Metabolic Diseases, at the Baylor Research Institute, in Dallas, Texas. The company revealed that the treatment indicated a slowdown in the progression of small fiber neuropathy. The results were also compared with those from currently approved enzyme based treatment options, as well as from untreated Fabry mice. PLX administered 1 mg/kg of PRX-102, to the Fabry mice, as compared to approved clinical doses of other drugs. Infusions were administered on a bi-weekly basis, for a period of 3-months.

The study results showed that PRX-102 was able to achieve a 53% reduction in the number of lba 1 spots, which is considered to be a marker for inflammation in the peripheral sensory nerves system. Dr. Yoseph Shaaltiel, the executive VP of the company, claimed that the results suggested that repeated infusions of the drug prevents activation and proliferation of the disease. He further stated that this change was not observed in the group being treated with other therapies.

Unfortunately for PLX, its investors have grown cautious of the stock, following poor results from the phase-3 clinical trials of its drug candidate alidornase alfa. The drug was developed as a treatment for cystic fibrosis, but the patients only saw their conditions worsen, upon administration of the drug. Although Protalix has claimed that the FDA has given the drug a positive review, the stock has kept declining ever since.

Protalix Biotherapeutics Inc (NYSEMKT:PLX) recorded a trade volume of 2.12 million, only to decline by 3.23% in the stock market, during the May 1 trading session, to close at $0.9 per share.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.